# of Displayed Technologies: 30 / 63

Applied Category Filter (Click To Remove): Oncology


Categories

T-cells with Enhanced Ability to Respond to Exogenous Ligands
TS-066052 — Novel T-cells expressing the IL-2a receptor to enhance cancer cell targeting.
The Need As interest in cell-based therapies, particularly for cancer treatment, continues to rise, there’s a critical need for therapeutic cells capable of robust proliferation in vivo. Existing methods relying on exogenous cytokines like IL-2 face challenges due to dose-limiting toxicity an…
  • College: OSU Wexner Medical Center
  • Inventors: Rubinstein, Mark
  • Licensing Officer: Schultz, Teri

Novel Antibodies Targeting IL-2
TS-066051 — Novel antibodies targeting IL-2 with the ability to inhibit IL-2 signaling through IL-2 Rαβg to a greater extent than through IL-2 Rβg.
IL-2 and its receptor IL-2R are known to play multiple roles in shaping the immune response, including both immune activation and tolerance. Expression of intermediate-affinity IL-2 receptors by different immune cell subsets determines cellular sensitivity to IL-2. However, the dynamic interplay bet…
  • College: OSU Wexner Medical Center
  • Inventors:
  • Licensing Officer: Schultz, Teri

Revolutionizing Cancer Immunotherapy with Novel Chimeric B-cell Epitope Peptide Vaccines
TS-065697 — Chimeric B-cell epitope peptide vaccines targeting human PD-L1 and/or CTLA-4 to induce immune response against the PD-1/PD-L1 signaling pathway.
The emergence of immune checkpoint inhibitors revolutionized cancer immunotherapy. Monoclonal antibodies targeting PD-1, PD-L1 and CTLA-4 have shown impressive clinical outcomes. The Need Despite their effectiveness, current monoclonal antibody treatments have limitations such as low response ra…
  • College: College of Medicine (COM)
  • Inventors: Kaumaya, Pravin
  • Licensing Officer: Schultz, Teri

Targeted Nanobody Technology for Precise Antineoplastic Treatment
TS-065460 — The Need Cancer remains one of the most pressing medical challenges worldwide, necessitating novel therapeutic approaches to combat its proliferation. Despite advancements, targeted therapies are often limited by immune responses or cumbersome production processes. There's a growing demand for …
  • College: College of Arts & Sciences
  • Inventors: Magliery, Thomas; Palmieri, Dario; Ryan-Simkins, Michael
  • Licensing Officer: Willson, Christopher

MicroRNA profile predicts colon cancer prognosis
TS-065453 — The Need: Colon cancer remains one of the most prevalent and lethal forms of cancer worldwide. Timely and accurate diagnosis is critical for effective treatment and improved patient outcomes. Current diagnostic methods often lack the precision and sensitivity needed for early detection and prognosi…
  • College: College of Medicine (COM)
  • Inventors: Croce, Carlo
  • Licensing Officer: Schultz, Teri

Intracellular Targeting by Monoclonal Antibodies
TS-064581 — Antibodies are essential therapeutic modalities for treating a plethora of different diseases, ranging from cancer, autoimmune disorders, degenerative diseases, and inflammation. The FDA approved the first antibody over three decades ago, and since more than 570 have been studied in clinical trials,…
  • College: College of Arts & Sciences
  • Inventors: Magliery, Thomas; Do, Jamie; Han, Jeong Min "Mina"; Zhu, Ian
  • Licensing Officer: Willson, Christopher

Magnetic Nanoparticles for Cancer Cell Classification
TS-064577 — Glioblastoma (GBM) is the most common malignant brain tumor accounting for 47.7% of all brain cancers. Unfortunately, treatments are limited, and survival is poor, with approximately only 40% living past the first-year post-diagnosis and 17% in the second year. The Need Developing drugs for cance…
  • College: College of Arts & Sciences
  • Inventors: Schultz, Zachary; Rist, David; Skardal, Aleksander; Venere, Monica
  • Licensing Officer: Willson, Christopher

Utilizing WT-IV-012 to improve immune checkpoint therapy in cancer treatment
TS-064262 — The Need Addressing the limitations of current melanoma therapies, there exists a critical need for innovative approaches that enhance the effectiveness of immune checkpoint therapeutics. Despite advancements in immunotherapy, a significant percentage of melanoma patients do not achieve complete re…
  • College: College of Arts & Sciences
  • Inventors: Burd, Craig; Aguilar-Valenzuela, Renan; Burd, Christin
  • Licensing Officer: Willson, Christopher

Multimeric Notch ligands based on IgM-like fusion molecular structures for activation of ligand-specific Notch signaling
TS-064248 — The Notch signaling pathway is important in immune cell differentiation and maturation. As a result, it has been shown that Notch receptor signaling can promote or suppress adaptive immune responses depending on the particular ligands and receptors involved. A set of native protein-inspired biolog…
  • College: OSU Wexner Medical Center
  • Inventors: Dikov, Mikhail; Carbone, David; Goruganthu, Uttam Lakshmi Mounika; Tchekneva, Elena
  • Licensing Officer: Willson, Christopher

Dual-payload Humanized Antibody-Drug Conjugate (DualADC) for targeted chemo-immunotherapy
TS-062822 — Humanized Antibody-drugs conjugate for chemo-immunotherapy of multiple cancer types
The Technology Dr. Margaret Liu and colleagues have developed a dual-payload antibody-drug conjugate (DualADC) for chemo-immunotherapy utilizing a new humanized antibody that targets CD276, a surface receptor that is overexpressed in Triple-negative Breast Cancers (TNBCs), lung cancer (including non…
  • College: College of Engineering (COE)
  • Inventors: Liu, Xiaoguang "Margaret"; Zhou, Lufang
  • Licensing Officer: Schworer, Adam

Tracking Breast Tissue Tumor Cavity after Lumpectomy
TS-062715 — Radiopaque biodegradable polymer for the tracking of the breast tissue tumor cavity after lumpectomy and other radiation therapy applications
Approximately 40% of women diagnosed with breast cancer undergo a lumpectomy procedure. Approximately 170,000 lumpectomie are performed each yaer in the United States. Typically, this operation is followed by radiation therapy to ensure there are no remaining cancerous cells in the region. It is t…
  • College: College of Engineering (COE)
  • Inventors: Metzler, Sandra; Elisha, Deji; Evans, Izzy; Fedro, Joseph; Krakovsky, Mia; Sherry, Adam; Skoracki, Roman
  • Licensing Officer: Zinn, Ryan

Addressing the Challenges in HCC Treatment with Innovative Technology
TS-062690 — Novel niclosamide analogues with improved bioavailability and mitigated dose-limiting toxicities.
Hepatocellular carcinoma (HCC) poses a significant global health challenge, being a predominant form of liver cancer with high mortality rates. The disease exhibits sexual dimorphism, disproportionately affecting males. The Need Despite the crucial role of androgen receptors (AR) in HCC progress…
  • College: College of Pharmacy
  • Inventors: Coss, Christopher; Cheng, Jeffrey; Cheng, Xiaolin; Kulp, Samuel; Li, Tom; Montgomery, Emma; Xing, Enming
  • Licensing Officer: Schultz, Teri

Transducin β-like protein 1 X-Linked Selective Degraders as Anti-cancer Therapeutics
TS-062685 — Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths. The most common cancers are breast, lung, colon and rectum and prostate cancers. The Need Current cancer treatments mainly rely on chemotherapy, radiation, surgery and bon…
  • College: College of Pharmacy
  • Inventors: Cheng, Xiaolin; Alinari, Lapo; Li, Pui-Kai "Tom"; Yang, Rui
  • Licensing Officer: Willson, Christopher

E-Cadherin-based Oncolytic Viral Cancer for Glioblastoma
TS-062682 — Glioblastoma (GBM) is the most common malignant brain tumor accounting for 47.7% of all brain cancers. Unfortunately, treatments are limited, and survival is poor, with approximately 40% living the first-year post-diagnosis and 17% in the second year. The Need Oncolytic viruses (OVs) are a prom…
  • College: College of Medicine (COM)
  • Inventors: Yu, Jianhua; Caligiuri, Michael; Xu, Bo
  • Licensing Officer: Taysavang, Panya

Selective Estrogen Receptor Beta Agonists
TS-062681 — According to the American Cancer Society, breast cancer is the most common cancer for women in the US, except for skin cancer. It comprised about 30% of all new female cancers each year. While breast cancer death rates have decreased over the last several decades, it remains the second leading cause…
  • College: OSU Wexner Medical Center
  • Inventors: Bennett, Chad; Wang, Dasheng
  • Licensing Officer: Taysavang, Panya

Selective Estrogen Receptor Beta Agonists
TS-062680 — According to the American Cancer Society, breast cancer is the most common cancer for women in the US, except for skin cancer. It comprised about 30% of all new female cancers each year. While breast cancer death rates have decreased over the last several decades, it remains the second leading cause…
  • College: College of Pharmacy
  • Inventors: Bennett, Chad; Wang, Dasheng
  • Licensing Officer: Taysavang, Panya

An innovative platform to enhance the efficacy of oncolytic virotherapy for cancer treatment through E-cadherin
TS-062679 — Glioblastoma (GBM) is the most common malignant brain tumor accounting for 47.7% of all brain cancers. Unfortunately, treatments are limited, and survival is poor, with approximately 40% living the first-year post-diagnosis and 17% in the second year. The Need Oncolytic viruses (OVs) are a prom…
  • College: College of Medicine (COM)
  • Inventors: Yu, Jianhua; Caligiuri, Michael; Xu, Bo
  • Licensing Officer: Taysavang, Panya

Bi-specific T-Cell Engagers as Anti-cancer Therapeutics
TS-062677 — Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths. The most common cancers are breast, lung, colon and rectum and prostate cancers. The Need Current cancer treatments mainly rely on chemotherapy, radiation, surgery and bon…
  • College: College of Medicine (COM)
  • Inventors: Caligiuri, Michael; Chan, Wing; Yu, Jianhua
  • Licensing Officer: Taysavang, Panya

Dual Androgen Receptor/AKR1C3 Inhibitors for Prostate Cancer
TS-062605 — The Need: Castration-resistant prostate cancer (CRPC) poses a significant challenge in oncology, with existing therapies often leading to resistance and disease progression. Key drivers of resistance include the androgen receptor (AR) and aldo-keto reductase family 1 member C3 (AKR1C3). Novel treat…
  • College: College of Pharmacy
  • Inventors: Li, Pui-Kai "Tom"; Cheng, Xiaolin; Kong, Xiaotian; Xing, Enming
  • Licensing Officer: Schworer, Adam

Noninvasive Biodosimetry Technology for Radiation Exposure Detection
TS-062556 — The Need: Noninvasive Biodosimetry Technology for Radiation Exposure Detection Radiation exposure poses significant health risks, including cancer and other illnesses, making it crucial for clinicians to accurately measure and assess the extent of radiation exposure. Existing methods often require …
  • College: College of Arts & Sciences
  • Inventors: Schultz, Zachary; Jacob, Naduparambil; Morder, Courtney
  • Licensing Officer: Willson, Christopher

Addressing the Treatment Gap in Advanced Liposarcoma
TS-062480 — Novel therapeutic compounds to treat advanced liposarcoma.
Patients diagnosed with advanced liposarcoma (LPS) face a significant treatment challenge, as current chemotherapy approaches exhibit low response rates of only 25%, leading to a dismal overall survival at 5 years, ranging between 20% to 34%. The Need Despite extensive efforts, there has been no s…
  • College: College of Medicine (COM)
  • Inventors: Beane, Joal; Goryunova, Marina; Hadad, Christopher; He, Yiran; Zhu, Hua
  • Licensing Officer: Schultz, Teri

Preventative Human T-cell leukemia virus type 1 vaccine
TS-062421 — The Need: Addressing the Global HTLV-1 Epidemic with a Novel Vaccine Human T cell leukemia virus type-1 (HTLV-1) is a significant global health concern, responsible for causing Adult T cell leukemia/lymphoma (ATLL) and human myelopathy/tropical spastic paraparesis (HAM/TSP). With over 10 million pe…
  • College: College of Veterinary Medicine
  • Inventors: Panfil, Amanda; Green, Patrick; Niewiesk, Stefan
  • Licensing Officer: Dahlman, Jason "Jay"

Unleashing the Power of Radiotherapy - Enhancing Tumor Oxygenation with Next-Gen Radiosensitizers
TS-062384 — , T2018-092, T2018-354, & T2020-216 This technology provides novel radiosensitizer compounds that are derivatives of papaverine designed to enhance tumor oxygenization without PDE-related side effects.
Papaverine is an FDA-approved phosphodiesterase 10A (PDE10A) inhibitor and its clinical use is due to these effects on blood pressure and vascular tone. However, it was found to also be a potent inhibitor of mitochondrial complex I. Papaverine’s mitochondrial complex I inhibition has been sho…
  • College: College of Medicine (COM)
  • Inventors: Denko, Nicholas; Benej, Martin; Haines, Ben; Mitton-Fry, Mark
  • Licensing Officer: Schultz, Teri

Modulation of Mismatch Repair and Genomic Stability by miR-155
TS-062322 — The Need The field of molecular biology faces a critical commercial need in the effective diagnosis, treatment, and prevention of cancer-related disorders associated with mismatch repair (MMR) dysfunction. Diseases such as Lynch Syndrome (LS) and hereditary non-polyposis colorectal cancer (HNPCC), …
  • College: College of Medicine (COM)
  • Inventors: Croce, Carlo; Valeri, Nicola
  • Licensing Officer: Willson, Christopher

Generation of T cell-specific CXCR3 Transgenic mouse
TS-062320 — The Need: Addressing Susceptibility to Cutaneous Leishmaniasis Cutaneous leishmaniasis, caused by the intracellular parasite Leishmania major and transmitted by sand flies, poses a significant threat to susceptible populations. This disfiguring disease results in large skin lesions, impacting both …
  • College: College of Arts & Sciences
  • Inventors: Satoskar, Abhay; Oghumu, Steve
  • Licensing Officer: Dahlman, Jason "Jay"

MicroRNA-Based Methods and Compositions for the Diagnosis, Prognosis and Treatment of Solid Cancers
TS-062318 — The Need Cancer is a significant health problem and a leading cause of death in developed countries. Solid cancers, including prostate, breast, lung, stomach, colon, and pancreatic cancers, pose particularly challenging diagnostic and treatment obstacles. Early detection of these cancers is crucial…
  • College: College of Medicine (COM)
  • Inventors: Croce, Carlo; Calin, George; Volinia, Stefano
  • Licensing Officer: Willson, Christopher

Diagnosis of Chemoresistant Ovarian Cancer.
TS-062306 — The Need Ovarian cancer is a significant health concern, being the leading cause of gynecological cancer-related deaths in the developed world. Current treatments, such as platinum-based chemotherapy, have limited success due to issues like late-stage diagnosis and chemoresistance. Identifying mole…
  • College: College of Medicine (COM)
  • Inventors: Croce, Carlo; Vecchione, Andrea
  • Licensing Officer: Willson, Christopher

Microrna-21, Mismatch Repair, and Colorectal Cancer
TS-062305 — The Need: Colorectal cancer (CRC) is a significant health concern, with a high incidence rate and limited treatment options, particularly regarding resistance to standard chemotherapy like 5-fluorouracil (5-FU). The management of CRC patients is complicated by the frequent occurrence of primary or a…
  • College: College of Medicine (COM)
  • Inventors: Croce, Carlo; Valeri, Nicola
  • Licensing Officer: Willson, Christopher

Advancing Cancer-Related Technology for Better Prognosis and Treatment
TS-062303 — The Need: Cancer continues to be a significant global health challenge, with conditions like non-small cell lung cancer (NSCLC) and hepatocellular carcinoma (HCC) often diagnosed at advanced stages, resulting in poor prognoses. Existing treatment methods, such as TRAIL-based therapy, face obstacle…
  • College: College of Medicine (COM)
  • Inventors: Croce, Carlo
  • Licensing Officer: Willson, Christopher

Diagnostics and Prognostics of Prostate Cancer
TS-062299 — The Need: Addressing Prostate Cancer Diagnostics and Therapeutics Prostate cancer remains a significant challenge in medical diagnosis and treatment, requiring advancements in diagnostics, therapeutics, and prognostics. Current approaches fall short in providing accurate and effective solutions, le…
  • College: College of Medicine (COM)
  • Inventors: Croce, Carlo
  • Licensing Officer: Willson, Christopher

Show More Technologies

Loading icon